Natixis Advisors, L.P. Astrazeneca PLC Transaction History

Natixis Advisors, L.P.

$51.3 Billion
Q3 2024

A detailed history of Natixis Advisors, L.P. transactions in Astrazeneca PLC stock. As of the latest transaction made, Natixis Advisors, L.P. holds 1,960,815 shares of AZN stock, worth $132 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares

1,960,815

Previous 1,843,653 6.35%

Holding current value

$132 Million

Previous $144 Million 6.25%

% of portfolio

0.3%

Previous 0.31%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$76.67 - $87.62 $8.98 Million - $10.3 Million	117,162 Added 6.35%	1,960,815 $153 Million
Q2 2024 Aug 01, 2024	BUY	$66.81 - $80.83 $18.6 Million - $22.5 Million	277,946 Added 17.75%	1,843,653 $144 Million
Q1 2024 Apr 25, 2024	BUY	$61.03 - $69.57 $19.2 Million - $21.9 Million	315,089 Added 25.19%	1,565,707 $106 Million
Q4 2023 Feb 06, 2024	BUY	$61.89 - $69.28 $4.85 Million - $5.42 Million	78,286 Added 6.68%	1,250,618 $84.2 Million
Q3 2023 Nov 13, 2023	BUY	$64.85 - $71.7 $2.44 Million - $2.7 Million	37,668 Added 3.32%	1,172,332 $79.4 Million
Q2 2023 Aug 15, 2023	BUY	$69.91 - $75.81 $9.25 Million - $10 Million	132,265 Added 13.19%	1,134,664 $81.2 Million
Q1 2023 May 11, 2023	BUY	$63.15 - $71.6 $7.53 Million - $8.54 Million	119,228 Added 13.5%	1,002,399 $69.6 Million
Q4 2022 Jan 27, 2023	SELL	$54.21 - $70.44 $1.18 Million - $1.53 Million	-21,730 Reduced 2.4%	883,171 $59.9 Million
Q3 2022 Nov 14, 2022	BUY	$53.02 - $135.75 $14.2 Million - $36.2 Million	266,986 Added 41.85%	904,901 $49.6 Million
Q2 2022 Aug 12, 2022	SELL	$59.26 - $71.14 $134,994 - $162,056	-2,278 Reduced 0.36%	637,915 $42.1 Million
Q1 2022 May 12, 2022	BUY	$55.72 - $67.12 $2.67 Million - $3.21 Million	47,865 Added 8.08%	640,193 $42.5 Million
Q4 2021 Feb 08, 2022	BUY	$54.02 - $63.83 $1,836 - $2,170	34 Added 0.01%	592,328 $34.5 Million
Q3 2021 Nov 15, 2021	BUY	$55.56 - $60.79 $5.59 Million - $6.12 Million	100,623 Added 20.47%	592,294 $35.6 Million
Q2 2021 Aug 12, 2021	BUY	$48.42 - $60.18 $3.52 Million - $4.38 Million	72,770 Added 17.37%	491,671 $29.5 Million
Q1 2021 May 05, 2021	BUY	$47.16 - $54.44 $2.65 Million - $3.06 Million	56,281 Added 15.52%	418,901 $20.8 Million
Q4 2020 Feb 12, 2021	SELL	$48.52 - $58.02 $375,496 - $449,016	-7,739 Reduced 2.09%	362,620 $18.1 Million
Q3 2020 Nov 12, 2020	SELL	$53.07 - $61.1 $1.03 Million - $1.19 Million	-19,499 Reduced 5.0%	370,359 $20.3 Million
Q2 2020 Aug 11, 2020	SELL	$43.1 - $55.31 $44,177 - $56,692	-1,025 Reduced 0.26%	389,858 $20.6 Million
Q1 2020 Apr 27, 2020	SELL	$37.79 - $51.33 $679,124 - $922,451	-17,971 Reduced 4.4%	390,883 $17.5 Million
Q4 2019 Feb 10, 2020	SELL	$42.46 - $50.46 $3.29 Million - $3.91 Million	-77,431 Reduced 15.92%	408,854 $20.4 Million
Q3 2019 Nov 12, 2019	SELL	$40.12 - $45.47 $5.22 Million - $5.92 Million	-130,215 Reduced 21.12%	486,285 $21.7 Million
Q2 2019 Aug 12, 2019	BUY	$37.28 - $41.68 $335,184 - $374,744	8,991 Added 1.48%	616,500 $25.4 Million
Q1 2019 May 15, 2019	SELL	$35.49 - $43.02 $402,314 - $487,674	-11,336 Reduced 1.83%	607,509 $24.6 Million
Q4 2018 Feb 13, 2019	BUY	$36.86 - $41.49 $1.41 Million - $1.59 Million	38,248 Added 6.59%	618,845 $23.5 Million
Q3 2018 Nov 13, 2018	BUY	$34.76 - $39.72 $280,478 - $320,500	8,069 Added 1.41%	580,597 $23 Million
Q2 2018 Aug 14, 2018	BUY	$34.55 - $37.05 $170,469 - $182,804	4,934 Added 0.87%	572,528 $0
Q1 2018 May 10, 2018	BUY	$32.97 - $36.63 $829,327 - $921,391	25,154 Added 4.64%	567,594 $19.8 Million
Q4 2017 Feb 14, 2018	BUY	$32.09 - $34.78 $871,949 - $945,042	27,172 Added 5.27%	542,440 $18.8 Million
Q3 2017 Nov 14, 2017	BUY	$28.96 - $34.0 $14.9 Million - $17.5 Million	515,268	515,268 $17.5 Million

Others Institutions Holding AZN

# of Institutions

1,361

Shares Held

475M

Call Options Held

5.39M

Put Options Held

3.75M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $208B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Astrazeneca PLC Transaction History